Nxera Pharma Reports Positive Phase 3 Trial Results for Daridorexant in South Korea
Nxera Pharma announced top-line results from its pivotal Phase 3 clinical trial of daridorexant in South Korea, showing that the study successfully met both primary and secondary endpoints in adult and elderly patients with insomnia. Daridorexant is a dual orexin receptor antagonist, a class of drugs that dampens wake signals in the brain to improve sleep. The 50 mg once-daily dose was tested in a multicenter, randomized, double-blind, placebo-controlled study. In this trial, participants receiving daridorexant experienced statistically significant improvements in subjective total s...